IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,668 shares of the medical research company’s stock after acquiring an additional 48 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in IQVIA were worth $3,313,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Versant Capital Management Inc grew its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $27,000. Rise Advisors LLC purchased a new position in IQVIA in the 1st quarter worth $31,000. Riverview Trust Co acquired a new stake in IQVIA during the 1st quarter worth about $32,000. Finally, International Assets Investment Management LLC purchased a new stake in IQVIA during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective for the company. Truist Financial lifted their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Finally, Barclays lifted their price objective on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $266.25.

IQVIA Stock Down 0.0 %

IQVIA stock opened at $248.77 on Thursday. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market capitalization of $45.35 billion, a PE ratio of 33.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The business has a 50 day simple moving average of $233.58 and a 200-day simple moving average of $234.51.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the business posted $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.